These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106 [TBL] [Abstract][Full Text] [Related]
7. [Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology]. van Herpen CM; de Mulder PH Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2613-8. PubMed ID: 10028361 [TBL] [Abstract][Full Text] [Related]
8. Current immunotherapeutic strategies in renal cell carcinoma. Amato RJ Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554 [TBL] [Abstract][Full Text] [Related]
9. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Wood CG Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296 [TBL] [Abstract][Full Text] [Related]
10. Interferon alpha for the treatment of advanced renal cancer. Ravaud A; Dilhuydy MS Expert Opin Biol Ther; 2005 Jun; 5(6):749-62. PubMed ID: 15952906 [TBL] [Abstract][Full Text] [Related]
11. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. Parton M; Gore M; Eisen T J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544 [TBL] [Abstract][Full Text] [Related]
12. New treatments for metastatic kidney cancer. Mancuso A; Sternberg CN Can J Urol; 2005 Feb; 12 Suppl 1():66-70; discussion 105. PubMed ID: 15780170 [TBL] [Abstract][Full Text] [Related]
13. Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II). Pandha H Integr Cancer Ther; 2004 Mar; 3(1):29-34. PubMed ID: 15035872 [No Abstract] [Full Text] [Related]
14. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282 [TBL] [Abstract][Full Text] [Related]
15. Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents. Köpke T; Bierer S; Wülfing C; Tiemann A; Hertle L; Herrmann E Expert Rev Anticancer Ther; 2009 Jun; 9(6):763-71. PubMed ID: 19496713 [TBL] [Abstract][Full Text] [Related]
16. [Renal cell carcinoma-interferon therapy, its clinical adaptation and limitations]. Noguchi S; Hosaka M Gan To Kagaku Ryoho; 1991 Nov; 18(14):2383-9. PubMed ID: 1952957 [TBL] [Abstract][Full Text] [Related]
18. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma. Little B; Young M; Ho KJ Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831 [TBL] [Abstract][Full Text] [Related]
19. [Chances for the success of cytokine therapy in metastatic renal cell cancer]. Kriegmair M Fortschr Med; 1992 Aug; 110(24):435-6. PubMed ID: 1398389 [No Abstract] [Full Text] [Related]
20. [Cytokine therapy for metastatic renal cell carcinoma]. Eto M; Naito S Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]